[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"site-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:site-infection":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100629560","incidence-of-ssi-after-cs-100629560",false,"NCT07476261","Incidence of Ssi After c.s","Incidence of Surgical Site Infection After Cesarean Section and Compliance With Surgical Site Infection Prevention Stratigies .","Inclusion Criteria:\n\n* All women who underwent cesarean section during the study period\n\nExclusion Criteria:\n\n* Patients who are lost to follow-up before completion of the 30-day postoperative assessment.\n\nPatients with immunocompromised conditions, such as:\n\nChronic corticosteroid therapy. Immunosuppressive treatment. Known HIV infection with severe immunosuppression .","FEMALE","18 Years","45 Years",{"count":20,"type":21},105,"ESTIMATED","OBSERVATIONAL","aim of the work is to evaluate adherence to preoperative , intraoperative, and postoperative infection preventive measures during cesarean section and to assess it s impact on the incidence of surgical site infection and maternal well-being during 30 days postoperative peroid.",[25],"Site Infection","NOT_YET_RECRUITING","2026-03-12",{"date":29,"type":30},"2026-03-17","ACTUAL",{"date":32,"type":21},"2026-05-01",{"date":34,"type":21},"2027-08-01",{"name":36,"class":37},"Assiut University","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":38},"100580649","vaginal-microbiota-and-post-cesarean-ssi-100580649","NCT06840041","Vaginal Microbiota and Post-cesarean SSI","The Relationship Between Vaginal Microbiota and Post-Cesarean Section Wound Infection","Inclusion Criteria:\n\n* Pregnant women undergoing elective or emergency cesarean section (CS).\n* Singleton pregnancy.\n* Cesarean section performed at ≥ 37 weeks of gestation.\n\nExclusion Criteria:\n\n* Use of antibiotics within two weeks prior to delivery.\n* Known immunodeficiency.\n* Chronic infections.\n* Ruptured membranes for more than 18 hours.",true,"40 Years",{"count":49,"type":21},160,"The goal of this observational study is to investigate the relationship between vaginal microbiota composition and the development of post-cesarean section wound infection in women undergoing cesarean delivery. The main question it aims to answer is:\n\nIs there a correlation between specific vaginal microbiota profiles and the incidence of post-cesarean section wound infection? Can specific bacterial taxa or diversity indices within the vaginal microbiota predict the risk of post-cesarean section wound infection?\n\nParticipants will:\n\nProvide vaginal swab samples pre-operatively and post-operatively. Undergo standard post-cesarean section care and follow-up. Have wound assessment performed per standard of care, and have data collected regarding wound infection status.\n\nHave demographic and clinical data collected, including but not limited to, antibiotic use, gestational age, and comorbidities.",[25,52],"Cesarean Section; Complications, Wound, Infection (Following Delivery)",[54,55,56],"cesarean section","SSI","vaginal microbiota","2025-06-13",{"date":59,"type":30},"2025-06-15",{"date":61,"type":21},"2025-06-30",{"date":63,"type":21},"2026-07-30",{"name":65,"class":37},"Al-Azhar University",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":73,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":38},"100549891","irrisept-solution-for-instrumented-spine-surgery-100549891","NCT06439953","Irrisept Solution for Instrumented Spine Surgery","Impact of Prophylactic Use of Irrisept Irrigation System for Spinal Instrumentation","Inclusion Criteria:\n\n* Age: 18+ years old\n* Indications: deformity, oncologic, degenerative, trauma\n* Standard layer-by-layer closure\n* Locoregional flap-based closure\n\nExclusion Criteria:\n\n* Acute\u002Fchronic open wounds (spine or non-spine)\n* On-going non-spinal infection within 30 days of index operation\n* Concurrent antibiotic use (for spine or non-spine infections)\n* History of prior spinal infection\n* Allergy to vancomycin or chlorhexidine\n* Suspicion for osteomyelitis\n* Other surgery within 90 days post-operatively fromm index\n* Concurrent enrollment in other trial","ALL",{"count":75,"type":21},200,"INTERVENTIONAL",[78],"NA","Various spine surgeons perform wound irrigation using saline mixed with vancomycin, relying on mechanical debridement of non-viable tissue, physical disruption of biofilm, and bacteriostatic effect against gram positive flora. When used as a powder, topical application of vancomycin has demonstrated increased risk of symptomatic seroma formation, which is an adverse outcome that often requires bedside or intra-operative aspiration. Broad-spectrum antiseptic agents, such as Irrisept, offer bacteriocidal properties to eliminate hardware inoculation, thereby minimizing the risk of deep space infection, while obviating the risk of seroma development.",[81,82,25,83,84,85,86,87],"Post-Op Complication","Spine Surgery","Surgical Site Infection","Spinal Instrumentation","Index Spinal Instrumentation","Layer-by-Layer Closure","Locoregional Flap-Based Closure","RECRUITING","2024-11-18",{"date":91,"type":30},"2024-11-20",{"date":93,"type":30},"2024-10-01",{"date":95,"type":21},"2026-09-30",{"name":97,"class":37},"Rhode Island Hospital"]